Login to Your Account

Bet on three Merrimack assets, Ipsen takes others for $1B+

By Randy Osborne
Staff Writer

Monday, January 9, 2017

In a potential $1 billion-plus deal that Cowen and Co. analyst Eric Schmidt described as "a necessary and favorable solution" for Merrimack Pharmaceuticals Inc.'s financial straits, the company is selling its approved pancreatic cancer drug Onivyde and its generic version of Doxil to Ipsen SA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription